Base de dados : MEDLINE
Pesquisa : C12.294.644.486 [Categoria DeCS]
Referências encontradas : 16286 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1629 ir para página                         

  1 / 16286 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376615
[Au] Autor:Kamalov AA; Takhirzade AM
[Ad] Endereço:Department of Urology and Andrology, Faculty of Fundamental Medicine, Lomonosov MSU, Moscow, Russia.
[Ti] Título:[Current approaches to conservative treatment of men with concomitant benign prostatic hyperplasia and erectile dysfunction].
[So] Source:Urologiia;(6):160-163, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article reviews the results of various conservative treatments for concomitant benign prostatic hyperplasia (BPH) and erectile dysfunction (ED). Phosphodiesterase type 5 (PDE5) inhibitors remain the first-line therapy for this category of patients taking into account their positive effect on both ED and BPH. The preferred treatment scheme includes PDE-5 inhibitor co-administered with 1-adrenoblocker. However, other combination treatments are considered promising, for example, a PDE-5 inhibitor with a 5-reductase inhibitor or a three-component treatment regimen: 1-adrenoblocker + 5-reductase inhibitor + PDE-5 inhibitor. All these approaches to treating patients with BPH and ED have demonstrated high efficiency and safety. Nevertheless, a limited number of randomized clinical trials and short-term observations suggest the need for further studies investigating the long-term outcomes of different treatment options for such patients.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/uso terapêutico
Antagonistas de Receptores Adrenérgicos alfa 1/uso terapêutico
Disfunção Erétil
Inibidores da Fosfodiesterase 5/uso terapêutico
Hiperplasia Prostática
[Mh] Termos MeSH secundário: Disfunção Erétil/tratamento farmacológico
Disfunção Erétil/etiologia
Disfunção Erétil/patologia
Disfunção Erétil/fisiopatologia
Seres Humanos
Masculino
Hiperplasia Prostática/complicações
Hiperplasia Prostática/tratamento farmacológico
Hiperplasia Prostática/patologia
Hiperplasia Prostática/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 0 (Adrenergic alpha-1 Receptor Antagonists); 0 (Phosphodiesterase 5 Inhibitors)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376611
[Au] Autor:Epifanova MV; Chalyi ME; Gvasaliya BR; Eremin II; Pulin AA; Nadelyaeva II; Artemenko SA; Galitskaya DA; Repin AM
[Ad] Endereço:Research Institute for Uronephrology and Human Reproductive Health, Moscow, Russia.
[Ti] Título:[New approaches for recovery of erectile function in patients after radical prostatectomy].
[So] Source:Urologiia;(6):138-143, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Prostate cancer (PCa) is one of the most common maligmancies and causes of death among men. Radical prostatectomy (RP) is optimal and recommended treatment modality for localized prostate cancer. More than half of all men undergoing surgery experience problems with erectile function and existing treatments do not provide a positive effect. Thus, there is a need for new approaches to the restoration of erectile function in patients after RP. One of these is the use of cell technologies, namely the stromal-vascular fraction and autologous platelet-rich plasma. This review examines the results of preclinical and clinical studies investigating the efficacy and safety of these treatment options in erectile dysfunction.
[Mh] Termos MeSH primário: Disfunção Erétil
Ereção Peniana
Complicações Pós-Operatórias/terapia
Prostatectomia/efeitos adversos
Neoplasias da Próstata/cirurgia
Recuperação de Função Fisiológica
[Mh] Termos MeSH secundário: Disfunção Erétil/etiologia
Disfunção Erétil/terapia
Seres Humanos
Masculino
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  3 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376613
[Au] Autor:Akhvlediani ND; Shvarts PG; Kirichuk YV
[Ad] Endereço:I.M. Sechenov First MSMU of Minzdrav of Russia, Moscow, Russia.
[Ti] Título:[Erectile dysfunction after nerve-sparing radical prostatectomy].
[So] Source:Urologiia;(6):149-152, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:Nerve-sparing radical prostatectomy remains the optimal curative treatment of prostate cancer in patients who want to maintain erectile function. Since its development, there has been a gradual decline in its effectiveness concerning the prevention of ED, which was associated with the currently more objective assessment of erectile function at both the pre- and post-operative stage. There is a knowledge gap in the precise understanding of which specific neural structures should be preserved with the nerve-sparing technique. At the same time, there have been proposed effective methods for visualizing the elements of the preserved vascular-neural bundle and estimating the degree of nerve-sparing.
[Mh] Termos MeSH primário: Disfunção Erétil
Complicações Pós-Operatórias/prevenção & controle
Prostatectomia
Neoplasias da Próstata/cirurgia
[Mh] Termos MeSH secundário: Disfunção Erétil/etiologia
Disfunção Erétil/prevenção & controle
Seres Humanos
Masculino
Prostatectomia/efeitos adversos
Prostatectomia/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  4 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463150
[Au] Autor:Gay HA; Sanda MG; Liu J; Wu N; Hamstra DA; Wei JT; Dunn RL; Klein EA; Sandler HM; Saigal CS; Litwin MS; Kuban DA; Hembroff L; Regan MM; Chang P; Michalski JM; Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium
[Ad] Endereço:Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri. Electronic address: hiramgay@wustl.edu.
[Ti] Título:External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):304-317, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The long-term effects of neoadjuvant androgen deprivation therapy (NADT) with radiation therapy on participant-reported health-related quality of life (HRQOL) have not been characterized in prospective multicenter studies. We evaluated HRQOL for 2 years among participants undergoing radiation therapy (RT) with or without NADT for newly diagnosed, early-stage prostate cancer. METHODS AND MATERIALS: We analyzed longitudinal cohort data from the Prostate Cancer Outcomes and Satisfaction with Treatment Quality Assessment Consortium to ascertain the HRQOL trajectory of men receiving NADT with external beam RT (EBRT) or brachytherapy. HRQOL was measured using the expanded prostate cancer index composite 26-item questionnaire at 2, 6, 12, and 24 months after the initiation of NADT. We used the χ or Fisher exact test to compare the shift in percentages between groups that did or did not receive NADT. Analyses were conducted at the 2-sided 5% significance level. RESULTS: For subjects receiving EBRT, questions regarding the ability to have an erection, ability to reach an orgasm, quality of erections, frequency of erections, ability to function sexually, and lack of energy were in a significantly worse dichotomized category for the patients receiving NADT. Comparing the baseline versus 24-month outcomes, 24%, 23%, and 30% of participants receiving EBRT plus NADT shifted to the worse dichotomized category for the ability to reach an orgasm, quality of erections, and ability to function sexually compared with 14%, 13%, and 16% in the EBRT group, respectively. CONCLUSIONS: Compared with baseline, at 2 years, participants receiving NADT plus EBRT compared with EBRT alone had worse HRQOL, as measured by the ability to reach orgasm, quality of erections, and ability to function sexually. However, no difference was found in the ability to have an erection, frequency of erections, overall sexual function, hot flashes, breast tenderness/enlargement, depression, lack of energy, or change in body weight. The improved survival in intermediate- and high-risk patients receiving NADT and EBRT necessitates pretreatment counseling of the HRQOL effect of NADT and EBRT.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/efeitos adversos
Braquiterapia/efeitos adversos
Terapia Neoadjuvante/efeitos adversos
Orgasmo
Ereção Peniana
Neoplasias da Próstata/terapia
Qualidade de Vida
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Antagonistas de Androgênios/uso terapêutico
Peso Corporal/efeitos dos fármacos
Peso Corporal/efeitos da radiação
Braquiterapia/métodos
Braquiterapia/estatística & dados numéricos
Mama/efeitos dos fármacos
Mama/efeitos da radiação
Distribuição de Qui-Quadrado
Terapia Combinada/efeitos adversos
Terapia Combinada/métodos
Terapia Combinada/estatística & dados numéricos
Depressão/etiologia
Disfunção Erétil/etiologia
Fadiga/etiologia
Fogachos/etiologia
Seres Humanos
Masculino
Meia-Idade
Terapia Neoadjuvante/métodos
Terapia Neoadjuvante/estatística & dados numéricos
Orgasmo/efeitos dos fármacos
Orgasmo/efeitos da radiação
Ereção Peniana/efeitos dos fármacos
Ereção Peniana/efeitos da radiação
Estudos Prospectivos
Antígeno Prostático Específico/sangue
Neoplasias da Próstata/sangue
Neoplasias da Próstata/patologia
Inquéritos e Questionários
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Androgen Antagonists); EC 3.4.21.77 (Prostate-Specific Antigen)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  5 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28463151
[Au] Autor:O'Callaghan ME; Raymond E; Campbell JM; Vincent AD; Beckmann K; Roder D; Evans S; McNeil J; Millar J; Zalcberg J; Borg M; Moretti K
[Ad] Endereço:South Australian Prostate Cancer Clinical Outcomes Collaborative; Freemasons Foundation Centre for Men's Health, University of Adelaide; Urology Unit, Repatriation General Hospital, SA Health; Flinders Centre for Innovation in Cancer. Electronic address: elspeth.raymond@health.sa.gov.au.
[Ti] Título:Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
[So] Source:Int J Radiat Oncol Biol Phys;98(2):318-337, 2017 06 01.
[Is] ISSN:1879-355X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PURPOSE: To identify, through a systematic review, all validated tools used for the prediction of patient-reported outcome measures (PROMs) in patients being treated with radiation therapy for prostate cancer, and provide a comparative summary of accuracy and generalizability. METHODS AND MATERIALS: PubMed and EMBASE were searched from July 2007. Title/abstract screening, full text review, and critical appraisal were undertaken by 2 reviewers, whereas data extraction was performed by a single reviewer. Eligible articles had to provide a summary measure of accuracy and undertake internal or external validation. Tools were recommended for clinical implementation if they had been externally validated and found to have accuracy ≥70%. RESULTS: The search strategy identified 3839 potential studies, of which 236 progressed to full text review and 22 were included. From these studies, 50 tools predicted gastrointestinal/rectal symptoms, 29 tools predicted genitourinary symptoms, 4 tools predicted erectile dysfunction, and no tools predicted quality of life. For patients treated with external beam radiation therapy, 3 tools could be recommended for the prediction of rectal toxicity, gastrointestinal toxicity, and erectile dysfunction. For patients treated with brachytherapy, 2 tools could be recommended for the prediction of urinary retention and erectile dysfunction. CONCLUSIONS: A large number of tools for the prediction of PROMs in prostate cancer patients treated with radiation therapy have been developed. Only a small minority are accurate and have been shown to be generalizable through external validation. This review provides an accessible catalogue of tools that are ready for clinical implementation as well as which should be prioritized for validation.
[Mh] Termos MeSH primário: Disfunção Erétil/etiologia
Gastroenteropatias/etiologia
Medidas de Resultados Relatados pelo Paciente
Neoplasias da Próstata/radioterapia
Retenção Urinária/etiologia
[Mh] Termos MeSH secundário: Idoso
Braquiterapia/efeitos adversos
Coleta de Dados/métodos
Seres Humanos
Masculino
Prognóstico
Estudos Prospectivos
Neoplasias da Próstata/patologia
Qualidade de Vida
Reprodutibilidade dos Testes
Estudos Retrospectivos
Transtornos Urinários/etiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE


  6 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453908
[Au] Autor:Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
[Ad] Endereço:Endocrinology Unit, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy.
[Ti] Título:Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
[So] Source:Andrology;5(4):671-678, 2017 07.
[Is] ISSN:2047-2927
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Despite their efficacy in the treatment of benign prostatic hyperplasia, the popularity of inhibitors of 5α-reductase (5ARIs) is limited by their association with adverse sexual side effects. The aim of this study was to review and meta-analyze currently available randomized clinical trials evaluating the rate of sexual side effects in men treated with 5ARIs. An extensive Medline Embase and Cochrane search was performed including the following words: 'finasteride', 'dutasteride', 'benign prostatic hyperplasia'. Only placebo-controlled randomized clinical trials evaluating the effect of 5ARI in subjects with benign prostatic hyperplasia were considered. Of 383 retrieved articles, 17 were included in this study. Randomized clinical trials enrolled 24,463 in the active and 22,270 patients in the placebo arms, respectively, with a mean follow-up of 99 weeks and mean age of 64.0 years. No difference was observed between trials using finasteride or dutasteride as the active arm considering age, trial duration, prostate volume or International Prostatic Symptoms Score at enrollment. Overall, 5ARIs determined an increased risk of hypoactive sexual desire [OR = 1.54 (1.29; 1.82); p < 0.0001] and erectile dysfunction [OR = 1.47 (1.29; 1.68); p < 0.0001]. No difference between finasteride and dutasteride regarding the risk of hypoactive sexual desire and erectile dysfunction was observed. Meta-regression analysis showed that the risk of hypoactive sexual desire and erectile dysfunction was higher in subjects with lower Q at enrollment and decreased as a function of trial follow-up. Conversely, no effect of age, low urinary tract symptom or prostate volume at enrollment as well as Q at end-point was observed. In conclusion, present data show that the use of 5ARI significantly increases the risk of erectile dysfunction and hypoactive sexual desire in subjects with benign prostatic hyperplasia. Patients should be adequately informed before 5ARIs are prescribed.
[Mh] Termos MeSH primário: Inibidores de 5-alfa Redutase/efeitos adversos
Dutasterida/efeitos adversos
Disfunção Erétil/induzido quimicamente
Finasterida/efeitos adversos
Hiperplasia Prostática/tratamento farmacológico
Disfunções Sexuais Psicogênicas/induzido quimicamente
[Mh] Termos MeSH secundário: Adulto
Idoso
Disfunção Erétil/fisiopatologia
Seres Humanos
Libido/efeitos dos fármacos
Masculino
Meia-Idade
Ereção Peniana/efeitos dos fármacos
Hiperplasia Prostática/enzimologia
Ensaios Clínicos Controlados Aleatórios como Assunto
Fatores de Risco
Comportamento Sexual/efeitos dos fármacos
Disfunções Sexuais Psicogênicas/fisiopatologia
Disfunções Sexuais Psicogênicas/psicologia
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (5-alpha Reductase Inhibitors); 57GNO57U7G (Finasteride); O0J6XJN02I (Dutasteride)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1111/andr.12353


  7 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29216611
[Au] Autor:Biundo B
[Ad] Endereço:Professional Compounding Centers of America, Houston, Texas. bbiundo@pccarx.com.
[Ti] Título:Compounding Opportunities in Urology.
[So] Source:Int J Pharm Compd;21(5):358-362, 2017 Sep-Oct.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There are a lot of options that pharmacists, including compounding pharmacists, can offer urologists to assist their patients. Compounding pharmacists are in a great position to offer unique, effective preparations for many of the conditions urologists treat on a daily basis. It would be well worth the time to learn a little about the conditions these specialists treat and become familiar with what you can offer.
[Mh] Termos MeSH primário: Composição de Medicamentos
Farmacêuticos
Urologia
[Mh] Termos MeSH secundário: Cistite Intersticial/tratamento farmacológico
Disfunção Erétil/tratamento farmacológico
Seres Humanos
Infertilidade/tratamento farmacológico
Masculino
Dor Pélvica/tratamento farmacológico
Induração Peniana/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE


  8 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29406063
[Au] Autor:Bennett N
[Ad] Endereço:Department of Urology, Northwestern University Feinberg School of Medicine, Galter Pavilion Suite: 20-150, 675 North Saint Clair Street, Chicago, IL 60611, USA. Electronic address: Nelson.Bennett@nm.org.
[Ti] Título:Sexual Dysfunction: Behavioral, Medical, and Surgical Treatment.
[So] Source:Med Clin North Am;102(2):349-360, 2018 Mar.
[Is] ISSN:1557-9859
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Sexual dysfunction affects both men and women and is responsible for 1 in 5 visits to urologist and/or gynecologists. It is important that treating providers use a logical and methodical approach to the diagnosis and treatment of this disorder. Behavioral therapy, coupled with oral medications, are very successful in treating erectile dysfunction. Complex and invasive therapies are used for more severe cases of sexual dysfunction and are best deployed by specialists.
[Mh] Termos MeSH primário: Disfunção Erétil/terapia
[Mh] Termos MeSH secundário: Disfunção Erétil/etiologia
Seres Humanos
Masculino
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180208
[Lr] Data última revisão:
180208
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180207
[St] Status:MEDLINE


  9 / 16286 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29240336
[Au] Autor:Allchorne P; Green J
[Ti] Título:Identifying Unmet Care Needs of Patients with Prostate Cancer To Assist with Their Success in Coping.
[So] Source:Urol Nurs;36(5):224-32, 2016 Sep-Oct.
[Is] ISSN:1053-816X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:In the United Kingdom, our Health Needs Assessment survey return rate of 42% identified unmet needs in subjects with prostate cancer. Subjects reported the greatest unmet need was related to erectile dysfunction. Other unmet needs were related to incontinence, tiredness, hot flashes, lower urinary tract symptoms, rectal bleeding, and relationship issues.
[Mh] Termos MeSH primário: Adaptação Psicológica
Determinação de Necessidades de Cuidados de Saúde
Neoplasias da Próstata/enfermagem
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Disfunção Erétil
Fadiga
Hemorragia Gastrointestinal
Fogachos
Seres Humanos
Relações Interpessoais
Sintomas do Trato Urinário Inferior
Masculino
Meia-Idade
Reto
Inquéritos e Questionários
Reino Unido
Incontinência Urinária
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180123
[Lr] Data última revisão:
180123
[Sb] Subgrupo de revista:N
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  10 / 16286 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28741569
[Au] Autor:Houslay MD
[Ad] Endereço:Institute of Pharmaceutical Sciences, 5th Floor Franklin-Wilkins Building, King's College London, London SE1 9NH, UK. Electronic address: miles.houslay@kcl.ac.uk.
[Ti] Título:Melanoma, Viagra, and PDE5 Inhibitors: Proliferation and Metastasis.
[So] Source:Trends Cancer;2(4):163-165, 2016 Apr.
[Is] ISSN:2405-8025
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Inhibitors of the cGMP-degrading phosphodiesterase (PDE) 5 have achieved blockbuster status in the treatment of penile erectile dysfunction (PED). Their repurposing is currently being proposed to treat certain solid tumours and various other diseases. In cruel irony, however, it appears from recent clinical studies that PDE5 inhibitors may increase the risk of malignant melanoma by negating newly identified brakes on proliferation and metastasis provided by PDE5A.
[Mh] Termos MeSH primário: Melanoma/patologia
Inibidores da Fosfodiesterase 5/efeitos adversos
Citrato de Sildenafila/efeitos adversos
[Mh] Termos MeSH secundário: Proliferação Celular/efeitos dos fármacos
Disfunção Erétil/tratamento farmacológico
Seres Humanos
Masculino
Inibidores da Fosfodiesterase 5/farmacologia
Inibidores da Fosfodiesterase 5/uso terapêutico
Citrato de Sildenafila/farmacologia
Citrato de Sildenafila/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phosphodiesterase 5 Inhibitors); BW9B0ZE037 (Sildenafil Citrate)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180117
[Lr] Data última revisão:
180117
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE



página 1 de 1629 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde